Latest news

• NHS to offer two new treatments for drug-resistant superbugs as part of a new subscription-style payment plan

  Fetcroja (cefiderocol). ... Fetcroja can be used to treat urinary tract infections, including kidney infections, and Zavicefta can be used to treat patients with pneumonia and sepsis.

• UK selects Shionogi’s Fetcroja for antimicrobial reimbursement scheme

  The antibiotic treats infections caused by aerobic Gram-negative bacteria. Shionogi’s novel antibiotic Fetcroja has been selected for inclusion in a pilot subscription reimbursement scheme, launched by the UK’s ... Fetcroja was launched in the UK in

• Shionogi’s novel antibiotic trial data published in The Lancet

  The second study, CREDIBLE-CR, evaluated Fetcroja as a treatment for a diverse range of serious Carbapenem-resistant (CR) infections. ... Fetcroja launched in the UK in September, launching as a treatment of infections caused by aerobic Gram-negative

• Shionogi's Gram-negative antibiotic launches in the UK

  Novel antibiotic is indicated for use against Gram-negative bacterial infections. Shionogi’s new antibiotic Fetcroja is now available for use in the UK for the treatment of infections caused by ... The launch of Shionogi's Fetcroja (cefiderocol) in the

• Modest meeting sees only two drugs recommended by CHMP

  The CHMP recommended a marketing authorisation of Japanese pharma company Shionogi’s antimicrobial drug Fetcroja (cefiderocol) for the treatment of infections caused by Gram-negative organisms in adults with limited treatment ... options. According to